Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia
The purpose of this study is to find a better, more convenient way to improve anemia results by increasing the amount of medication given at 3 week intervals. Researchers want to know if giving a higher dose of Procrit® and intravenous (IV) iron once every 3 weeks would give better results in treating anemia without the need for more office visits.
Checked against the public recordLast updated Mar 5, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- University of Louisville
- Interventions being studied
- Drug: Epoetin Alfa plus Iron
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically confirmed small cell or non small cell lung cancer * Stage III or Stage IV lung cancer * Platinum containing chemotherapy induced anemia (\< 10 g/dl Hb) * Cancer related anemia (\<10 g/dl Hb) at time of initiation of chemotherapy * ECOG performance status of 0,1, or 2 * Informed consent * Age\>18 * Expected to receive platinum based outpatient chemotherapy for at least nine weeks Exclusion Criteria: * Pregnant women * Intolerance to epoetin alfa or parenteral iron * More than 2 cycles of the planned platinum chemotherapy at time of enrollment * Chronic GI bleed (\> than 4 weeks positive hemoccult or gastroccult) * Ferritin \> 500 mg/dl * Anemia due to other causes than cancer or chemotherapy * Previous parenteral iron therapy * Uncontrolled hypertension (systolic BP \> 160, diastolic \> 100 mmHg)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- James Graham Brown Cancer CenterLouisville, Kentucky
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 5, 2018. Always confirm current availability with the study team.